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Abstract:  
Objectives:  Children with Crohn’s disease may present with malnutrition and linear growth 
impairment which can be secondary to insufficient caloric intake, chronic inflammation, 
malabsorption, and suppression of growth-promoting hormones. We evaluated clinical, 
serologic, and genetic data to determine risk factors for impaired anthropometrics in Crohn’s 
disease at diagnosis.  
Methods:  Our study evaluated 772 children newly diagnosed with Crohn’s disease, 
inflammatory phenotype, enrolled in the RISK Stratification Project to determine the factors 
associated with anthropometric impairment. Data were collected on demographics, growth 
parameters, disease location, serologic and immunologic markers, and disease severity. We 
performed a genome-wide association study of genetic polymorphisms associated with 
inflammatory bowel disease. Regression analysis determined associations between 
anthropometrics and clinical, serologic, and genetic variables.  
Results: There were 59 (7%) children with height z-score <-2, 126 (14%) with a weight z-
score <-2, and 156 (17%) with a BMI z-score <-2. Linear growth impairment was associated 
with hypoalbuminemia (p=0.0052), elevated granulocyte-macrophage colony stimulating 
factor auto-antibodies (GM-CSF Ab) (p=0.0110), and elevated CBir antibodies against 
flagellin (p=0.0117). Poor weight gain was associated with female gender (p=0.0401), 
hypoalbuminemia (p=0.0162), and thrombocytosis (p=0.0081). Malnutrition was associated 
with hypoalbuminemia (p=0.0061) and thrombocytosis (p=0.0011). Children with moderate 
or severe disease had lower weight (p=0.02 and p=1.16×10-6, respectively) and BMI z-scores 
(p=2.7×10-3 and p=1.01×10-6, respectively) than children with quiescent and mild disease. 
There was no association between age of diagnosis, Tanner stage, or disease location and 
having impaired anthropometrics. There was no genome-wide association between the 
genetic polymorphisms and the serologic variables and anthropometric measurements.  
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Conclusions: This is the largest study evaluating growth in treatment-naïve children with 
Crohn’s disease, inflammatory phenotype. It is the first study to use genome-wide sequencing 
to assess for genetic determinants of growth impairment. GM-CSF auto-antibodies and CBir 
antibodies are more likely to be elevated in children with growth impairment. Future 
investigations should evaluate the relationship between genetic polymorphisms, pathologic 
immune responses, and the biological pathways regulating growth. 
Keywords: inflammatory bowel disease; children; growth impairment; malnutrition; genetic 
polymorphism 
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What is Known: 
• Children with Crohn’s disease often have impaired linear growth and malnutrition.  
• Specific genetic polymorphisms involved with inflammatory bowel disease are 
associated with the age of onset, disease behavior, location, or severity of the disease.  
What is New: 
• At time of diagnosis of Crohn’s disease, children with linear growth impairment are 
more likely to have elevated granulocyte-macrophage colony stimulating factor auto-
antibodies and elevated CBir antibodies against flagellin.  
• No specific genetic sequences were associated with growth impairment or 
malnutrition. 
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Introduction 
Crohn’s disease is a chronic intestinal inflammatory condition which may adversely 
affect growth and nutrition. Approximately 100-300 per 100,000 people have inflammatory 
bowel disease (IBD) in North America (1). Among children with Crohn’s disease, 13-58% 
will have poor linear growth; those with pre-pubertal disease onset may develop permanent 
growth impairment, despite receiving therapy with biologics (2, 3). Previous investigations 
demonstrated that linear growth impairment is associated with ileal disease, NOD2 
mutations, and elevated GM-CSF auto-antibodies (4).  
Specific serum biomarkers and cytokines are elevated in patients with active IBD. 
Chronic inflammation alters the actions of growth-promoting hormones and leads to low 
levels of insulin-like growth factor (IGF-1) (5). Subsequently, growth hormone (GH) 
resistance and a slower progression through puberty develop (6). Thayu M, et al (7), 
demonstrated that inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis 
factor-α (TNF-α), are increased at diagnosis and decrease with treatment; children with IBD 
who experienced an improvement in their height z-score over time had an increase in IGF-1 
and decrease in IL-6 and TNF-α. Thus, chronic elevation in inflammatory cytokines and 
immune-mediated GH resistance contribute to growth impairment.     
Elucidation of risk factors beyond nutritional status and disease severity are important 
in understanding growth delay and its management. We performed a cross-sectional study of 
children with Crohn’s disease enrolled in the RISK Stratification Project, which established a 
national database of clinical, genetic, and histologic information. We hypothesized that 
multiple variables, including serology, genetics, inflammatory cytokines, disease severity, 
and pubertal development, would be associated with growth impairment in children with 
Crohn’s disease.    
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
Methods 
Study Population 
The RISK Stratification Project was funded by Crohn’s and Colitis Foundation and 
conducted by Pediatric Research Organization for Kids with Intestinal Inflammatory Diseases 
(PRO-KIIDS) to identify baseline biological and microbial factors that determine 
complicated stricturing and penetrating pediatric Crohn’s disease (8). 28 medical centers 
enrolled 1813 children under 18 years with a new diagnosis of IBD from 2008-2012. Only 
children with Crohn’s disease diagnosed by their primary physician were included, and 
children with ulcerative colitis or indeterminate IBD were excluded. Children were excluded 
if they had incomplete data collected on the disease location, were lost to follow-up, or 
developed stricturing or penetrating disease within 90 days of diagnosis. Ultimately, 913 
children with an inflammatory phenotype of Crohn’s disease participated in the project, 
which is the largest multicenter, prospective study of pediatric patients with Crohn’s disease. 
A database and biorepository were created, including DNA, plasma, stool, and mucosal 
biopsies. For our study, we excluded children who did not have all the serologic, 
immunologic, and genetic sequencing data collected. Our study evaluated 772 children with 
non-stricturing and non-penetrating Crohn’s disease at the time of diagnosis. Children with 
stricturing or penetrating disease were excluded as they may have a different clinical 
phenotype and genotype than children with the inflammatory phenotype. The Indiana 
University School of Medicine Institutional Review Board and the RISK Ancillary Study 
Steering Committee approved this study.   
Data Collection 
Demographic data and each child’s height, weight, and body mass index (BMI) were 
recorded during enrollment into the RISK Stratification Project. Disease severity was 
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determined using the Pediatric Crohn’s Disease Activity Index (PCDAI) and the Physician 
Global Assessment (PGA). The PCDAI includes growth parameters. Disease location was 
classified as upper intestinal tract, ileum, or colon. Children were included in all disease 
location classifications where they had active disease. Laboratory results were recorded for 
hemoglobin, platelets, eosinophil count, erythrocyte sedimentation rate (ESR), C-reactive 
protein (CRP), and albumin. Titer levels were obtained using an enzyme-linked 
immunosorbent assay for anti-Saccharomyces cerevisiae antibodies (ASCA), anti-neutrophil 
cytoplasmic antibodies (ANCA), anti-outer membrane protein C of E. Coli antibodies 
(ompC), antibodies against flagellin of Clostridium taxa (CBir), granulocyte-macrophage 
colony stimulating factor auto-antibodies (GM-CSF Ab), and antibodies to Pseudomonas 
fluorescens (I2). The antibody titers were measured at Cedars-Sinai Hospital, except for the 
GM-CSF auto-antibodies which were measured at Cincinnati Children’s Hospital Medical 
Center. Serum levels of the cytokines IGF-1, IL-6, and TNF-α were obtained at Cincinnati 
Children’s Hospital Medical Center. Additionally, the Tanner stages of pubertal development 
were recorded at diagnosis, either through self-report or examination by a physician. 
DNA was isolated from peripheral blood samples. Genotyping for the subjects was 
conducted at Emory University School of Medicine on the Immunochip, an Illumina Infinium 
High-Density array (9, 10). The Immunochip contains 196,524 loci from 12 autoimmune and 
inflammatory diseases. Quality control (QC) was conducted on genotype data to exclude 
single nucleotide polymorphisms (SNPs) with minor allele frequency <3%, missing rate 
>5%, Hardy-Weinberg Equilibrium test p-value <10-4, and individuals with a missing rate 
>10%.  
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Statistical Analysis 
The height, weight, and BMI z-scores of each child were calculated at enrollment. 
Clinical variables were analyzed for an association with (1) linear growth impairment, (2) 
poor weight gain, and (3) malnutrition. Linear growth impairment was defined as a height z-
score <-2, and children with poor weight gain had a weight z-score <-2. A BMI z-score <-2 
identified children with malnutrition. The demographic variables included were age at 
diagnosis, gender, and race. Race was self-reported as Caucasian, African-American, Asian, 
or having a mixed or unknown race.  For the laboratory variables, we only included those 
which had less than 20% of the data missing, which resulted in CRP, IGF-1, IL-6, TNF-α, 
and I2 being excluded. We defined children in pre- or mid-puberty as Tanner stages I-III. 
Children near complete pubertal development were classified as Tanner stages IV or V. We 
conducted a Kruskal-Wallis rank sum test to evaluate for an association between Tanner 
stage, age at diagnosis, and anthropometric measurements.  
Children with early-onset IBD may have a different clinical phenotype and genotype 
than children and adolescents diagnosed at an older age. We used the Chi-square test to 
determine if there was an association between linear growth impairment or poor weight gain 
and any of the clinical variables in children six years old and younger and children older than 
six years. A p-value less than 0.05 was considered significant.    
We analyzed if an association existed between each of the growth parameters and 
disease severity. The PGA classifies patients as having quiescent, mild, moderate, or severe 
disease. The PCDAI provides a score from 0-100. Patients have inactive disease if the 
PCDAI <10, mild disease for 10-27.5, moderate disease for 30-37.5, and severe disease for 
40-100 (11). A t-test compared the mean height, weight, and BMI z-scores with the PGA and 
PCDAI. The z-scores of children with quiescent or mild disease were combined in order to 
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ensure sufficient power for the analysis. The z-scores of those with quiescent or mild disease 
were compared to children with moderate disease and to those with severe disease. Children 
who have a PCDAI ≤30 were analyzed against children who had a PCDAI >30. A 
multivariate regression analysis evaluated for an association between age, gender, height, 
weight, and BMI z-scores, and disease severity. A chi-square analysis evaluated if there was 
an association between disease severity and children ≤6 years and children >6 years old. 
Univariate and multivariate logistic regression analyses were performed to determine 
the association between the clinical variables and the presence of linear growth impairment, 
poor weight gain, or malnutrition as defined by height, weight, and BMI z-scores. The first 
study outcome evaluated children with z-scores <-2. A separate analysis assessed height, 
weight, and BMI z-scores as continuous variables and included the normal clinical reference 
values for each variable. A p-value < 0.05 was considered significant. These multivariate 
models were built using the statistical software R v3.4.   
A genome-wide association study (GWAS) was conducted using PLINK software to 
determine if an association exists between growth impairment and genetic polymorphisms 
known to be involved in IBD (12). Population stratification was performed with Eigenstrat 
(13). Race was excluded from the analysis as it or the first two principal components from 
Eigenstrat did not have a significant association with height, weight, and BMI z-scores. After 
quality control, 121,487 SNPs and 772 subjects were included in the GWAS. 159 of the 163 
SNPs associated with IBD were included (14). If the SNPs were in exons, the surrounding 
genes were reported. A p-value of 4×10-7 was considered significant, and a p-value <5×10-5 
was used to identify genes with strong evidence of association. A final multivariate 
regression evaluated if there is an association between the laboratory studies, auto-antibodies, 
genotype data, and anthropometric z-scores <-2. The regression was also conducted using the 
z-scores as continuous outcomes in order to identify all significant covariates. Integrity 
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Pathway Analysis evaluated the common molecular pathways and gene functions of the 
genes of highest significance (15).   
Results 
Study population 
The characteristics of the 772 children are shown in Table 1. The mean (+/-SD) age of 
the study population at the time of diagnosis of Crohn’s disease was 11.6 +/- 3.1 years. The 
median age was 12 years with a range of 1 to 17 years. 44 children were 6 years old or 
younger. 286 (37%) were female. The study was composed of 637 (82%) Caucasian, 46 (6%) 
African-American or mixed race, 29 (4%) Asian, and 60 (8%) children of unknown race. 446 
of the 772 (58%) children had Tanner staging recorded at diagnosis (Table, Supplemental 
Digital Content 1, http://links.lww.com/MPG/B698, Tanner Staging). 244 children (55%) 
were in pre-puberty (Tanner stage 1), 104 (23%) were in mid-puberty (Tanner stages II-III), 
and 98 (22%) were in late puberty (Tanner stages IV-V) (Table 1). Of the 244 children in 
Tanner stage 1, 17 (7%) had a height z-score <-2, 33 (13.5%) had a weight z-score <-2, and 
35 (14%) had a BMI z-score<-2. There was no significant association between Tanner stage 
and age at diagnosis (p=0.90). Additionally, there was no association between Tanner stage 
and height (p=0.91), weight (p= 0.74), or BMI (p= 0.7128) z-scores <-2.    
Anthropometrics at diagnosis 
The study cohort had a mean height z-score of -0.30 +/- 1.13, mean weight z-score of 
-0.69 +/- 1.28, and mean BMI z-score of -0.80 +/- 1.42. There were 59 (7%) children with 
height z-score <-2, 126 (14%) children with a weight z-score <-2, and 156 (17%) children 
with a BMI z-score <-2. There was no significant difference in the anthropometric z-scores in 
children with very early-onset IBD ages 6 years and younger and children over age 6 years.  
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Disease severity and location 
751 (97%) of the children had disease severity classified according to the PGA and 
PCDAI. The PCDAI range was 0-82.5. There was no significant difference in disease 
severity in children ≤6 years old and children >6 years old (p=0.5382 for PGA, p=1 for 
PCDAI). In a univariate analysis using the PGA, children who had moderate disease (p=0.02) 
or severe disease (p=1.16×10-6) had lower weight z-scores than children with quiescent or 
mild disease. The same result was found using the PCDAI (Table, Supplemental Digital 
Content 2, http://links.lww.com/MPG/B698, growth parameters according to disease 
severity). Children with PCDAI >30 had lower weight z-scores than those with PCDAI ≤30 
(p=1.81×10-6). The BMI z-scores in children with quiescent or mild disease were 
significantly higher than those who had moderate disease (p=2.7×10-3) and severe disease 
(p=1.01×10-6). There was no statistically significant association between the disease severity 
using the PGA or PCDAI and the height z-scores. A multivariate regression including age 
and gender did not show a significant difference in anthropometrics and disease severity 
(Table, Supplemental Digital Content 3, http://links.lww.com/MPG/B698, disease severity 
including confounding variables).  
Each disease location, classified as either upper intestinal, ileal, and 
ileocolonic/colonic disease, was not associated with anthropometric impairment (Table 2). To 
ensure accuracy of this finding, a t-test was conducted comparing the mean z-scores for 
height (p=0.29), weight (p=0.53), and BMI (p=0.87) in children with isolated colonic disease 
and children with ileal or ileocolonic disease.  
Clinical variables associated with anthropometrics 
Specific laboratory studies and auto-antibodies were associated with height, weight, 
and BMI z-scores in both regression analyses: using a discrete outcome of z-scores <-2 and 
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using z-scores as a continuous outcome. The significant clinical variables associated with a 
height z-score <-2 were hypoalbuminemia and elevated GM-CSF auto-antibodies (Table 3). 
Children with a weight z-score <-2 were more likely to be female and have hypoalbuminemia 
and thrombocytosis. Children who had a BMI z-score <-2 were also more likely to have 
hypoalbuminemia and thrombocytosis. The results of the continuous data analysis are in the 
Text, Supplemental Digital Content 4, http://links.lww.com/MPG/B698 and Table, 
Supplemental Digital Content 5, http://links.lww.com/MPG/B698. The laboratory studies and 
auto-antibodies that were not significantly associated with impaired anthropometrics, 
included ESR, ASCA, ANCA, and OmpC (Table 2).   
Additionally, we assessed for an association between age at diagnosis and the 
presence of each antibody, without including anthropometrics. There was a significant 
association between age and the titer levels of ASCA IgA (p=6.4x10-7), ASCA IgG 
(p=1.2x10-38), GM-CSF auto-antibodies (p=4.4x10-93), I2 (p=2.1x10-7), CBir antibodies 
(p=2.9x10-49), and ANCA (p=1.1x10-23). The antibodies with a positive correlation with age 
were ASCA IgA (r=0.12), ASCA IgG (r=0.11), GM-CSF auto-antibodies (r=0.10), and 
ANCA (r=0.10). I2 (r= -0.08) and CBir antibodies (r= -0.08) had a negative correlation with 
age.   
Outcome of genome-wide association study analysis 
There was no genome-wide association between the 121,487 SNPs and 
anthropometrics. No genome-wide significance was observed for height, weight, or BMI z-
scores <-2 or when assessed as a continuous outcome. For a height z-score <-2, the genes 
containing SNPs which were most closely associated with significance were the following: 
OR5D14, OR5L1, OR4C6, OR5D13, KCNH8, EFHB, TAP2, PAPOLG, VAV3, and HLA-
DOB. These genes are involved with multiple physiological processes, including DNA 
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synthesis, cell signaling, and antigen presentation (Table 4). The genes with the highest 
evidence of association with poor weight gain included: RMI2, GLP2R, C8orf87, SKAP2, 
and ANXA6. These genes are active in DNA repair, nutrient absorption in enterocytes, cell 
exocytosis, and cell survival. The genes with SNPs most strongly associated with 
malnutrition included: CCR7, SMARCE1, and TAGAP. These genes are involved with 
antigen presentation and B and T cell activation and migration. The SNPs located in non-
coding genes were not included, since the pathophysiology and clinical significance are 
unknown. The results of the continuous data analysis are in the Text, Supplemental Digital 
Content 4 and Table, http://links.lww.com/MPG/B698, Supplemental Digital Content 6, 
http://links.lww.com/MPG/B698. 
Discussion 
This is the largest study examining clinical, serologic, and genetic factors associated 
with anthropometric impairment in children with non-stricturing and non-penetrating Crohn’s 
disease at diagnosis. The mean anthropometrics of our cohort were similar to the much 
smaller cohort examined by Pfefferkorn M, et al, which assessed linear growth outcomes 
over two years in children with Crohn’s disease (3). Thrombocytosis, hypoalbuminemia, 
elevated GM-CSF auto-antibodies, and elevated CBir antibodies were significant factors 
associated with linear growth impairment. Thrombocytosis, hypoalbuminemia, and female 
gender were associated with poor weight gain. Age, including children with early onset IBD, 
and disease location did not identify children with impaired anthropometrics. No genetic 
sequences were associated with anthropometric impairment.      
Previous investigations demonstrated that serum antibodies are associated with age at 
diagnosis. ASCA is more common in older children whereas CBir1 is more frequent under 
age 7. Our study replicated these results and observed significant associations between other 
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antibodies and age. Thus, there are differences in the immunologic response to microbial 
antigens based on age (16).  
Earlier research has demonstrated there is a correlation between low z-scores for 
weight and height at the time of diagnosis of Crohn’s disease and positive antibodies 
associated with IBD, particularly ASCA. Higher titers of ASCA antibodies were associated 
with a lower weight z-score (17). However, in our much larger study, a significant 
association occurred between elevated GM-CSF auto-antibodies and a height z-score <-2, but 
not ASCA. CBir antibodies were associated with growth impairment in the continuous data 
analysis of height z-scores. GM-CSF auto-antibodies have previously been demonstrated to 
be associated with GH resistance and linear growth impairment, particularly in patients with a 
NOD2 mutation (4). This association was modified by small bowel location and weight at 
diagnosis. In a related murine model, GM-CSF neutralization in NOD2-deficient mice was 
associated with hepatic growth hormone resistance. Elevated levels of GM-CSF auto-
antibodies will lead to activated macrophages, increased intestinal permeability, and a higher 
likelihood of ileal and stricturing and/or penetrating behavior (18, 19). Additionally, patients 
with GM-CSF auto-antibodies have impaired phagocytosis by neutrophils which protects the 
mucosal barrier (19). Dysregulation of GM-CSF likely leads to a poor innate immune 
response to microbial antigens, and in combination with increased intestinal permeability and 
bacterial translocation, growth hormone resistance develops. 
While our study did not demonstrate any SNPs to be associated with impaired 
anthropometrics, previous investigations have shown several SNPs involved in IBD are 
associated with age of onset, disease behavior, location, or severity (20-23). Importantly, 
there are many associations between clinical factors and genetic sequences, but these do not 
necessarily indicate a causal relationship. Future investigations should evaluate the biological 
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pathways of these genes to elucidate the pathogenic mechanisms leading to growth 
impairment. 
 Limitations in our study include the following: (1) limitation to only children who had 
non-stricturing and non-penetrating Crohn’s disease, (2) the cross-sectional analysis limited 
to children who had a single measurement of anthropometrics at diagnosis, before therapy 
was initiated, and (3) the PCDAI includes anthropometric measurements. The SNPs 
evaluated were not specifically associated with growth. With improved understanding of the 
functions of the SNPs associated with IBD, future studies may elicit the SNPs which place 
children at highest risk for poor growth. However, our study included a very large cohort of 
children with treatment-naïve Crohn’s disease who were evaluated with twenty-one clinical 
and serologic variables and extensive genetic sequencing. It is the most comprehensive study 
evaluating growth at the time of diagnosis and establishes a foundation to investigate growth 
over time.  
Currently, a comprehensive evaluation of anthropometrics, lab results, and endoscopic 
findings remains necessary for diagnosis and management. Future investigations should 
evaluate pathogenic mechanisms for poor growth and identify factors that support catch-up 
growth. Our study demonstrated an association between GM-CSF auto-antibodies and CBir 
antibodies and linear growth impairment; additional research should investigate the 
relationship between the genetic polymorphisms, the immune response, and hormonal 
pathways regulating growth in children with Crohn’s Disease.    
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Table Legend: 
Table 1. Demographics and Tanner Staging of Study Cohort 
N 772
Age (years)  
     Mean 11.6 (+/- 3.1) 
     Range 1-17 
     Median  12  
Male 486 (63%)  
Race  
     Caucasian 637 (82%)  
     African-American or mixed  46 (6%)  
     Asian 29 (4%)  
     Unknown  60 (8%)  
Tanner Staging (N=446)  
     I 244 (55%) 
     II 65 (15%) 
     III 39 (9%) 
     IV 51 (11%) 
     V 47 (10%) 
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Table 2. Univariate regression analysis of clinical variables associated with height, 
weight, and BMI z-scores <-2  
  Height z-score <-2 Weight z-score <-2 BMI z-score <-2 
Clinical Variable 
(N=772) OR (95% CI) p-value OR (95% CI) 
p-
value OR (95% CI) 
p-
value 
 Age at diagnosis 0.95 (0.88-1.04) 0.26 0.98 (0.92-1.04) 0.44 0.95 (0.90-1.01) 0.08 
 Gender 1.4 (0.82-2.38) 0.21 1.31 (0.89-1.91) 0.17 0.78 (0.54-1.11) 0.17 
 Upper GI tract 
(N=429) 1.01 (0.60-1.74) 0.96 1.25 (0.85-1.84) 0.26 1.52 (1.07-2.19) 0.02 
 Ileum (N=560) 1.01 (0.57-1.85) 0.99 0.79 (0.53-1.18) 0.24 0.99 (0.69-1.47) 1.00 
 Colon (N=599) 0.8 (0.45-1.49) 0.46 1.26 (0.80-2.05) 0.34 1.82 (1.16-2.96) 0.01 
 Hemoglobin 
(g/dL)  1.01 (0.96-1.03) 0.68 1.01 (0.98-1.03) 0.46 1.01 (0.99-1.03) 0.13 
 Platelets (109/L) 
1.002(1.0005-
1.0037) 0.01 









(109/L)   0.98 (0.82-1.00) 0.61 1 (0.99-1.00) 0.35 1 (1.00-1.01) 0.12 
 ESR (mm/hr) 1.01 (0.99-1.02) 0.20 1 (0.99-1.01) 0.52 1.01 (1.00-1.02) 0.01 
 Albumin (g/dL) 0.47 (0.30-0.73) 0.001 0.54 (0.40-0.74) 
1.18×1
0-4 0.53 (0.39-0.70) 
1.37×1
0-5 
 ASCA IgA 
(EU/mL) (N=758) 1.01 (0.99-1.02) 0.25 1.01 (1.00-1.01) 0.16 1 (1.00-1.01) 0.37 
 ASCA IgG 
(EU/mL) (N=758) 1 (0.99-1.01) 0.51 1 (0.99-1.01) 0.79 1 (1.00-1.01) 0.52 
 ANCA (EU/mL) 
(N=758) 1.01 (0.99-1.01) 0.25 1 (0.99-1.01) 0.84 0.99 (0.99-1.00) 0.37 
 GM-CSF (mcg/ml) 
(N=734) 1.03 (1.00-1.05) 0.02 0.99 (0.96-1.01) 0.49 0.99 (0.96-1.01) 0.26 
 CBir (EU/mL) 
(N=758) 1.01 (1.00-1.01) 0.01 1 (1.00-1.01) 0.35 0.99 (0.99-1.00) 0.98 
 OmpC (EU/mL) 
(N=758) 0.99 (0.97-1.01) 0.83 1 (0.98-1.01) 0.92 1 (0.99-1.01) 0.68 
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Table 3. Multivariate binary regression analysis of clinical variables associated with 




Odds Ratio Standard Error p-value 
Albumin (g/dL) 0.50 0.25 0.0052 
GM-CSF auto-antibodies 
(mcg/ml) (N=734) 




Odds Ratio Standard Error p-value 
Female 1.56 0.22 0.0401 
Platelets (109/L) 1.00 0.001 0.0081 




Odds Ratio Standard Error p-value 
Platelets (109/L) 1.00 0.001 0.0011 
Albumin (g/dL) 0.64 0.16 0.0061 
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Table 4. Genetic sequences associated with anthropometric z-scores using discrete 
outcome analysis 
Gene p-value Gene Function Common 
Pathway 
Height z-score <-2 
OR5D14, 
OR5L1,  




4.29×10-6 Olfactory receptor proteins 
KCNH8, EFHB 1.22×10-5 Potassium and calcium cell signaling 
VAV3 5.91×10-5 Cytoskeleton protein synthesis 
PAPOLG 4.91×10-5 DNA synthesis 
 
TAP2 2.15×10-5 Transport protein for antigen 
processing Antigen 
presentation 
HLA-DOB 6.53×10-5 MHC Class II-β cell signaling 
Weight z-score <-2 
SKAP2 4.70×10-5 Protein in Src pathway for cell growth 
and survival Cell signaling 
ANXA6 7.72×10-5 Cell signaling for exocytosis 
GLP2R 1.29×10-5 Nutrient absorption in enterocytes 
 
C8orf87 3.91×10-5 Codes for uncharacterized protein 
 
RMI2 1.59×10-5 DNA repair 
 
BMI z-score < -2 
TAGAP 7.90×10-5 Rho GTPase-activator protein Cell signaling 
CCR7, 
SMARCE1 
2.25×10-5 B and T cell activation and migration, 
dendritic cell maturation; chromatin 
remodeling 
Antigen 
presentation 
 
